(PRWEB) March 31, 2016
North America’s leading provider of outsourced clinical, sales and field service teams in the medical devices and diagnostic sectors, Novasyte, is pleased to announce the appointment of Dr. James Fox and Michael Kagnoff to the Board of Directors.
Dr. Fox joins Novasyte with 30 years of experience in the global healthcare industry, originally leading the start-up of Invetech, an international contract research and development company specializing in medical device and instrument products. Under Dr. Fox's leadership, Invetech grew rapidly into a group of businesses which included Vision BioSystems, one of the world's foremost cancer IVD companies.
“We are thrilled to have James join our Board,” said Board Chairman, Pete Gleeson. “His combined expertise in contract research and development brings unparalleled knowledge to our team that I’m confident will help us realize our long range goals.”
Dr. Fox has extensive experience in global technology and healthcare businesses. He led the start up in 1986 of Invetech, an Australian contract research and development company that specializes in healthcare products and complex instruments for international markets. Invetech was merged with Australian Securities Exchange listed Vision Systems Limited in 1993, and Dr. Fox took over as Group Managing Director of the combined entity. In January 2007, Vision Systems Ltd., then a leading global cancer diagnostics company, was acquired by Danaher Corporation. Following the acquisition of Vision Systems, Dr. Fox left the company to work in an advisory capacity on several boards globally.
Prior to Invetech, Dr. Fox spent seven years working as a consultant and managing director with Cambridge (UK)-based PA Technology. Dr. Fox currently serves as Chairman of GenMark Diagnostics Inc. and as a director of Cambridge (UK) based TTP Group (UK). In the recent past, Dr. Fox was a director of Air New Zealand Ltd and Chairman of Biota Pharmaceuticals Inc. Dr. Fox received his Bachelor's, Master's and Ph.D. degrees in engineering from the University of Melbourne.
“In addition to James, we are excited to broaden our expertise in the life sciences and technology legal realm with the addition of Michael Kagnoff to our Board,” said Gleeson. “His expertise in both public and private sectors will be invaluable as we continue to expand services in our specialized verticals.”
With well over 20 years of experience advising boards of directors on legal and business matters in the life sciences and technology arena, Mr. Kagnoff has long established his expertise in the healthcare industry. Prior advisory topics include but are not limited to strategic market advancement, transactions, governance and employee compensation. Since April 2008, Mr. Kagnoff has served as a partner at global law firm, DLA Piper. Prior to his current role, he was a partner at Heller Ehrman LLP for five years. Mr. Kagnoff received a B.A. and B.S. degree from the University of Pennsylvania, and a J.D. from the University of California, Berkeley's Boalt Hall School of Law.
Novasyte partners with medical device and diagnostic companies, offering outsourced sales, clinical support and field service solutions. Our flexible model enables us to deploy and manage field-based teams that expand and contract to meet our clients' customer-facing needs. Program success is tracked and measured with our real-time business intelligence analytics that provide our clients with critical insights into their most important resources - their people and their customers.